Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Adult pure red cell aplasia is a rare acquired aplastic anemia characterized by a severe normocytic anemia with normal peripheral leukocyte and platelet counts, reticulocytopenia, high serum ferritin and transferrin saturation levels and isolated, almost complete absence of erythroblasts in the bone marrow with normal granulopoesis and megakaryopoesis. It presents with signs of severe anemia (fatigue, lethargy, pallor, intolerance of physical exercise and exertional dyspnea) in the absence of hemorrhagic symptoms.
Biomarker and diagnostic research for adult pure red cell aplasia has been reported in the published literature.
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE2. Research is primarily sponsored by academic and government institutions.
90 publications have been identified in PubMed for adult pure red cell aplasia. Research spans Case Report / Case Series (58%), Basic Science / Preclinical (14%), and Clinical Trial Publication (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 52 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 6:24 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about adult pure red cell aplasia
Laboratory research | 13 | 14% |
Clinical study results | 10 | 11% |
Disease patterns and progression | 8 | 9% |
Research summaries | 3 | 3% |
New treatment approaches | 3 | 3% |
Testing and diagnosis research | 1 | 1% |
Arnold DE (2026). [PMID: 41370196](https://pubmed.ncbi.nlm.nih.gov/41370196/). *Blood advances*. [Case Report / Case Series]
Yamashita N (2026). [PMID: 41943918](https://pubmed.ncbi.nlm.nih.gov/41943918/). *Br J Haematol*. [Basic Science / Preclinical]
Wang H (2026). [PMID: 42010264](https://pubmed.ncbi.nlm.nih.gov/42010264/). *Signal Transduct Target Ther*. [Clinical Trial Publication]
Yang L (2026). [PMID: 41922159](https://pubmed.ncbi.nlm.nih.gov/41922159/). *American journal of hematology*. [Epidemiology / Natural History]
Lecornec N (2026). [PMID: 41498485](https://pubmed.ncbi.nlm.nih.gov/41498485/). *American journal of hematology*. [Epidemiology / Natural History]
Spataro F (2026). [PMID: 41940437](https://pubmed.ncbi.nlm.nih.gov/41940437/). *Br J Haematol*. [Basic Science / Preclinical]
Deng K (2026). [PMID: 41576344](https://pubmed.ncbi.nlm.nih.gov/41576344/). *Blood advances*. [Basic Science / Preclinical]
Zhang R (2026). [PMID: 40587957](https://pubmed.ncbi.nlm.nih.gov/40587957/). *Acta Haematol*. [Basic Science / Preclinical]
Hayase N (2026). [PMID: 41692453](https://pubmed.ncbi.nlm.nih.gov/41692453/). *Internal medicine (Tokyo, Japan)*. [Case Report / Case Series]
Janson M (2026). [PMID: 41905276](https://pubmed.ncbi.nlm.nih.gov/41905276/). *Cancer Treat Rev*. [Review / Meta-Analysis]
AI-curated news mentioning adult pure red cell aplasia
Updated Sep 15, 2026
A recent study published in PubMed explores acquired pure red cell aplasia as a secondary condition linked to indolent mature T-cell lymphoid malignancy. This research contributes to the understanding of the disease's pathophysiology and potential treatment avenues.
A recent case report highlights the emergence of pure red cell aplasia following COVID-19 infection, contributing to the understanding of post-viral complications. This literature review may inform future research and clinical approaches to managing similar cases.
A recent study published in PubMed explores the use of Roxadustat for treating pure red cell aplasia associated with anti-EPO antibodies. This research could provide insights into alternative treatment options for patients suffering from this rare condition.